Six rhesus monkeys (Macaca mulatta), age 20 to 25 years, weighing at least 6 kg with bilateral normal ocular examinations by biomicroscopy and tonometry, were screened and trained for the study. The monkeys were housed in the Wisconsin National Primate Research Center at the Wisconsin Institutes for Medical Research complex, and all experiments were done in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. After the monkeys were acclimated to the facility and trained to receive topical treatments consciously, the experiments were initiated as described below. Monkeys were anesthetized with intramuscular (IM) ketamine (10 to 20 mg/kg initial), followed by intravenous pentobarbital anesthesia (8 to 15 mg/kg initial; 5 to 10 mg/kg supplemental) for the perfusion outflow facility studies and endotracheal inhalation isofluorane anesthesia for the surgical interventions. For the pneumatography studies, 0.2 mg/kg IM midazolam plus 0.04 mg/kg IM atropine was administered. During surgery, animals received systemic monitoring including heart rate, respiration rate and/or end-tidal CO2, SpO2, temperature, and blood pressure. During our measurements of intraocular oxygen, special efforts were made to decrease FiO2 to approach 21% (room air levels), with maintenance of peripheral blood saturation (SaO2) to baseline levels of 93% to 97%. Following each ocular surgery, the eye received subconjunctival injections of gentamycin and methylprednisolone acetate, followed by administration of polymixin/neomycin/bacitracin antibiotic ointment into the conjunctival sac. In cases of persistent inflammation, 1% atropine ointment was also applied to the eye. Postprocedure analgesia with buprenorphine (0.005 to 0.02 mg/kg IM at 6- to 12-hour intervals) or carprofen in multimodal analgesia where animals received buprenorphine (0.005 to 0.02 mg/kg IM at intervals of not more than 20 hours) and carprofen (2 to 4 mg/kg orally, intravenous, subcutaneous, or IM), butorphanol (0.05 to 0.2 mg/kg IM at 2- to 4-hour intervals), meloxicam (0.1 to 0.2 mg/kg orally), and/or flunixin meglumine (1 to 2 mg/kg, 1 to 2 times daily IM) was administered for up to 3 days following all surgical procedures, and/or at any other time deemed necessary by the principal investigator, the collaborators at the UW, or attending veterinary staff. The analgesia dosing was chosen depending on the animal's signs of pain (e.g., squinting, swollen eyelids, rubbing of the eyes, or tearing). The surgical and sham-operated eyes were observed by the research staff during daily treatment (including topical 1% tropicamide and 10% phenylephrine) for 2 weeks to monitor surgical recovery.